- Home
- VEEE vs APVO Comparison
VEEE vs APVO Comparison
Compare VEEE & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VEEE
- APVO
- Stock Information
- Founded
- VEEE 1994
- APVO 2016
- Country
- VEEE United States
- APVO United States
- Employees
- VEEE N/A
- APVO N/A
- Industry
- VEEE Marine Transportation
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- VEEE Industrials
- APVO Health Care
- Exchange
- VEEE Nasdaq
- APVO Nasdaq
- Market Cap
- VEEE 5.8M
- APVO 4.1M
- IPO Year
- VEEE 2021
- APVO N/A
- Fundamental
- Price
- VEEE $2.10
- APVO $2.26
- Analyst Decision
- VEEE
- APVO Strong Buy
- Analyst Count
- VEEE 0
- APVO 1
- Target Price
- VEEE N/A
- APVO $5,920.00
- AVG Volume (30 Days)
- VEEE 133.2K
- APVO 124.7K
- Earning Date
- VEEE 08-07-2025
- APVO 08-19-2025
- Dividend Yield
- VEEE N/A
- APVO N/A
- EPS Growth
- VEEE N/A
- APVO N/A
- EPS
- VEEE N/A
- APVO N/A
- Revenue
- VEEE $13,153,262.00
- APVO N/A
- Revenue This Year
- VEEE N/A
- APVO N/A
- Revenue Next Year
- VEEE N/A
- APVO N/A
- P/E Ratio
- VEEE N/A
- APVO N/A
- Revenue Growth
- VEEE N/A
- APVO N/A
- 52 Week Low
- VEEE $1.88
- APVO $2.10
- 52 Week High
- VEEE $9.30
- APVO $381.10
- Technical
- Relative Strength Index (RSI)
- VEEE 40.77
- APVO 29.91
- Support Level
- VEEE $2.08
- APVO $2.10
- Resistance Level
- VEEE $2.72
- APVO $2.80
- Average True Range (ATR)
- VEEE 0.21
- APVO 0.17
- MACD
- VEEE 0.00
- APVO 0.01
- Stochastic Oscillator
- VEEE 26.18
- APVO 13.41
About VEEE Twin Vee PowerCats Co.
Twin Vee PowerCats Co is a designer, manufacturer, and marketer of recreational and commercial power boats to use for fishing, diving and water skiing, and commercial activities including transportation, eco-tours, fishing, and diving expeditions. The company offers various boat models, including Twin Vee 400 GFX2 CC, Twin Vee 280 GFX2 CC, and Twin Vee 260 Center Console STX, among others. Its products are marketed under two brands, Twin Vee for its catamarans, or dual-hull vessels, and Aquasport for its V-hull boats. The company sells its boats through a network of independent boat dealers across North America, the Caribbean, and Central America who resell the boats to the end user, Twin Vee customers.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.